ADHD Diagnoses, Stimulant Use Surge Outside U.S.
the Psychiatry Advisor take:
The growing “medicalization” of attention deficit/hyperactivity disorder (ADHD) has led to a dramatic rise in prescriptions for stimulants used to treat the condition around the world.
Peter Conrad, PhD, a sociologist at Brandeis University, Waltham, Massachusetts, says that the reason isn’t that fewer kids in the U.S. are being diagnosed. Rather, ADHD diagnoses are rising and prescriptions of stimulants are surging in other countries, particularly the United Kingdom and Germany.
Conrad examined the incidence of ADHD in five countries: Brazil, France, Germany, Italy and the United Kingdom. In the 1990s, fewer than 1% of children in the U.K. had been diagnosed with ADHD. Today, that figure is about 5%. And in Germany, prescriptions for ADHD drugs rose 500% between 1998 and 2008, from 10 million daily doses to 53 million.
Writing in the journal Social Science and Medicine, Conrad attributes the growth of ADHD globally to five trends. He says that pharmaceutical companies have been effective in marketing ADHD drugs and convincing regulators to relax restrictions on them. Also, talk therapy is taking a back seat to using medications to treat psychiatric conditions in general. Third, mental health professionals around the world are adopting DSM standards for ADHD, which have a lower threshold for diagnosis.
Conrad also accused ADHD advocacy groups of aligning closely with drug makers to promote medication as treatment. And the widespread availability of information on ADHD and self-diagnosis tools available online lead people to ask their clinicians for a prescription.
ADHD pandemic causes researchers to fidget | BrandeisNOW
Attention deficit/hyperactivity disorder (ADHD) has been medicalized in the United States since the 1960s. Primarily used in North America until the 1990s, ADHD diagnosis and treatment have increasingly been applied internationally.
After documenting the expansion of ADHD in a global context, this paper presents five brief international examples examining ADHD usage and expansion: the United Kingdom, Germany, France, Italy and Brazil. We then identify and describe several vehicles that facilitate the migration of the ADHD diagnosis: the transnational pharmaceutical industry; the influence of western psychiatry; moving from ICD to DSM diagnostic criteria; the role of the Internet including the related advent of easily accessible online screening checklists; and advocacy groups.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Amisulpride May Be Most Effective Antipsychotic for Negative Symptoms in Schizophrenia
- Frustrations With Prior Authorization: A Thorn in the Side of Clinicians
- Efficacy of Drugs for Psychosis, Relapse Prevention for Bipolar Depression, Mania
- No Evidence of Cognitive Impairment With Lisdexamfetamine Dimesylate in ADHD
- Plasma Autoantibodies Possible Biomarker for Schizophrenia
- Substance-Induced Psychosis Associated With Development of Schizophrenia, Bipolar Disorder
- Neuropsychiatric Events May Be Linked to Nitrated Nucleosome Levels in Lupus
- New APA Guideline Recommendation for Treatment of Alcohol Use Disorder
- Reducing PTSD Symptoms: Propranolol Before Reactivation Therapy
- Cannabis Use Associated With Subsequent Psychotic Experiences in Adolescents
- Intervention Improves Quality of Life, Agitation in Nursing Home Patients With Dementia
- Cognitive Enhancement Therapy Beneficial for Neurocognitive Function in Autism
- The Crisis of Physician Suicides: Past and Present
- Affective Temperaments in Bipolar Have a Significant Impact on Functional, Clinical Outcomes of Mania
- Ketamine: A Promising Agent for Managing Treatment-Resistant Depression